This clinical trial is focused on a skin condition called pyoderma gangrenosum, which is characterized by painful ulcers. The study is testing a treatment called spesolimab, also known by its code name BI 655130. Spesolimab is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein. The trial will compare the effects of spesolimab to a placebo, which is a substance with no active medication, to see if spesolimab is more effective in treating this condition.

The purpose of the study is to determine if spesolimab can help achieve complete healing of the ulcers caused by pyoderma gangrenosum. Participants in the study will receive either spesolimab or a placebo and will be monitored over a period of time to see if their ulcers heal completely. The study will last up to 52 weeks, with the main focus on the first 26 weeks to see if the ulcers close completely and remain healed for at least two weeks.

Throughout the study, participants will have regular check-ups to monitor their progress. The study aims to provide valuable information on whether spesolimab can be a safe and effective treatment option for people suffering from pyoderma gangrenosum. The ultimate goal is to find a treatment that can help reduce the area of the ulcers and improve the quality of life for those affected by this condition.